INT11154

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1992
Last Reported 2011
Negated 2
Speculated 1
Reported most in Body
Documents 149
Total Number 151
Disease Relevance 96.23
Pain Relevance 6.29

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (EGFR) cell morphogenesis (EGFR) Golgi apparatus (EGFR)
endoplasmic reticulum (EGFR) intracellular (EGFR) enzyme binding (EGFR)
Anatomy Link Frequency
skin 4
neck 3
head 3
platelet 2
epithelial cell 2
EGFR (Homo sapiens)
EGFR - T790M (1)
Pain Link Frequency Relevance Heat
cINOD 67 100.00 Very High Very High Very High
cocaine 32 100.00 Very High Very High Very High
COX2 9 99.86 Very High Very High Very High
antagonist 68 99.28 Very High Very High Very High
Morphine 2 99.20 Very High Very High Very High
Inflammation 381 97.64 Very High Very High Very High
Kinase C 41 97.40 Very High Very High Very High
chemokine 213 96.68 Very High Very High Very High
Cannabinoid 72 93.88 High High
fibrosis 101 93.60 High High
Disease Link Frequency Relevance Heat
Cancer 4899 100.00 Very High Very High Very High
Disease 1852 100.00 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 108 100.00 Very High Very High Very High
Skin Cancer 79 100.00 Very High Very High Very High
Chronic Renal Failure 55 100.00 Very High Very High Very High
Advanced Or Metastatic Breast Cancer 963 99.88 Very High Very High Very High
Inflammatory Breast Neoplasms 547 99.84 Very High Very High Very High
Ovarian Cancer 310 99.76 Very High Very High Very High
Glioma 243 99.76 Very High Very High Very High
Toxicity 1096 99.70 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
After binding to EGFR, the Fc region of cetuximab remains exposed, and may be recognized by Fc?
EGFR Binding (binding) of
1) Confidence 0.48 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721306 Disease Relevance 0.57 Pain Relevance 0
TKD shows that it is involved in EGFR dimerization, auto- and transphosphorylation
EGFR Binding (dimerization) of
2) Confidence 0.48 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.16 Pain Relevance 0
Cetuximab is a monoclonal antibody that specifically binds to the EGFR, thereby inhibiting downstream signal transduction pathways [29].
EGFR Binding (binds) of
3) Confidence 0.47 Published 2005 Journal BMC Cancer Section Body Doc Link PMC1266352 Disease Relevance 1.06 Pain Relevance 0
The extracellular domain has 4 subunits, which exist in a compact, tethered auto-inhibited condition in the absence of a ligand.47 Cetuximab prevents ligand binding to EGFR, inhibits receptor dimerization, and therefore blocks downstream signaling.
EGFR Binding (binding) of
4) Confidence 0.47 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886327 Disease Relevance 0.14 Pain Relevance 0
Cancer cells expressing EGFR and ErbB2 are nonresponsive to inhibitors targeting one of these two proteins.63 Similarly, overexpression of ErbB3 also confers resistance to EGFR inhibitors.64 Expression of hepatocyte growth factor and c-Met dependent signaling is also an alternative pathway for signaling conferring resistance (seen in approximately 20% of patients with acquired resistance to TKIs).65 Finally, interactions between EGFR and the insulin growth factor receptor (IGF-1R) can provide resistance to agents targeting EGFR.66
EGFR Binding (interactions) of in hepatocyte associated with cancer
5) Confidence 0.47 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886327 Disease Relevance 0.27 Pain Relevance 0
This antibody, cetuximab, binds to EGFR with higher affinity than its murine counterpart.41–44
EGFR Binding (binds) of
6) Confidence 0.47 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886327 Disease Relevance 0.33 Pain Relevance 0
The mechanism of action of panitumumab involves binding of panitumuab to the EGFR with inhibition of ligand binding of EGFR.
EGFR Binding (binding) of
7) Confidence 0.47 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886332 Disease Relevance 0.77 Pain Relevance 0
Cetuximab is a monoclonal antibody binding specifically to EGFR and thus inhibiting downstream signal transduction pathways [27].
EGFR Binding (binding) of
8) Confidence 0.47 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1524973 Disease Relevance 0.85 Pain Relevance 0
The cell line G-112 is one such line that bound Mab against EGFR but very weakly bound QD-EGF Fig. 1B,C and Suppl.
EGFR Binding (bound) of
9) Confidence 0.46 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2894859 Disease Relevance 0.89 Pain Relevance 0.03
As pertuzumab inhibits heterodimerization of HER1/HER2, this rash was considered as possibly related to treatment.
HER1 Neg (inhibits) Binding (heterodimerization) of associated with exanthema
10) Confidence 0.45 Published 2009 Journal Japanese Journal of Clinical Oncology Section Body Doc Link PMC2661001 Disease Relevance 1.33 Pain Relevance 0.07
binding to the extracellular domain of EGFR, which results in cell-growth inhibition, induction of apoptosis and decreased production of EGF [7].
EGFR Binding (binding) of associated with apoptosis
11) Confidence 0.44 Published 2007 Journal World J Surg Oncol Section Body Doc Link PMC2147013 Disease Relevance 0.69 Pain Relevance 0
The EGFR (also known as ErbB-1/HER1) is a 170-kDa transmembrane glycoprotein that consists of an extracellular domain that recognizes and binds to specific ligands, a hydrophobic transmembrane domain, which is involved in interactions between two receptors within the cell membrane, and an intracellular domain that contains the tyrosine kinase enzymatic activity.
EGFR Binding (recognizes) of
12) Confidence 0.44 Published 2010 Journal Current Gerontology and Geriatrics Research Section Body Doc Link PMC2905690 Disease Relevance 0.34 Pain Relevance 0
Ligand binding of these ErbB receptors causes formation of heterodimers or homodimers, in turn inducing autophosphorylation of specific tyrosine kinase residues within conserved catalytic domains of the ErbB receptors.
ErbB Binding (binding) of
13) Confidence 0.42 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.35 Pain Relevance 0
The independent variables were evaluated with simple linear regression to identify the factors that were associated with low serum phosphorus level and low eGFR at week 24.
eGFR Binding (associated) of
14) Confidence 0.42 Published 2010 Journal AIDS Res Ther Section Body Doc Link PMC3020664 Disease Relevance 0.07 Pain Relevance 0
Gefitinib (Iressa, ZD-1839) acts as a competitive inhibitor of ATP for binding to the EGFR tyrosine kinase pocket [23] and inducing the formation of inactive EGFR dimers and homodimers [24].
EGFR Binding (binding) of
15) Confidence 0.41 Published 2010 Journal Mol Cancer Section Body Doc Link PMC2828989 Disease Relevance 0.56 Pain Relevance 0.03
In stomach cancer, breast cancer, head and neck cancer, and colorectal cancer, several studies on the association of COX-2, VEGF, and EGFR with angiogenesis have already been reported [13, 15-18].
EGFR Binding (association) of in head associated with colorectal cancer, breast cancer, head & neck cancer and stomach cancer
16) Confidence 0.41 Published 2010 Journal Journal of the Korean Society of Coloproctology Section Body Doc Link PMC2998021 Disease Relevance 1.72 Pain Relevance 0.05
It binds exclusively EGFR and its heterodimers, blocks receptor dimerisation, tyrosine kinase phosphorylation, and signal transduction.
EGFR Binding (binds) of
17) Confidence 0.38 Published 2007 Journal Mol Cancer Section Body Doc Link PMC1852117 Disease Relevance 0.67 Pain Relevance 0
Abnormalities in expression of two of the known ligands of the EGFR, transforming growth factor alpha and epidermal growth factor, occur frequently in ductal adenocarcinoma of the human pancreas.
EGFR Binding (ligands) of in pancreas associated with adenocarcinoma and congenital anomalies
18) Confidence 0.37 Published 1992 Journal J. Pathol. Section Abstract Doc Link 1538276 Disease Relevance 0.42 Pain Relevance 0.07
Nevertheless, this study still suggested a significant association between EGFR copy number and response and survival [20].
EGFR Binding (association) of
19) Confidence 0.37 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2432064 Disease Relevance 0.18 Pain Relevance 0
At least six different ligands, known as epidermal growth factor-like ligands, bind to EGFR [27].
EGFR Binding (bind) of
20) Confidence 0.37 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2972555 Disease Relevance 0.67 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox